K Number
K240864
Device Name
PacePro Wire
Manufacturer
Date Cleared
2024-05-24

(57 days)

Product Code
Regulation Number
870.1330
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The PacePro Wire is intended for use to introduce and position interventional devices within the chambers of the heart, including those used for transcatheter aortic valve procedures. Additionally, the PacePro Wire can be used for temporary intracardiac pacing by transmitting an electrical signal from an external pulse generator to the heart.
Device Description
The proposed PacePro Wire is a guidewire that includes functions for a structural wire and a pacing wire (temporary intracardiac pacing by transmitting an electrical signal from an external pulse generator to the heart.). Throughout the submission this will be referred to as either PacePro Wire or Opsens Pacing Wire (OPW). These two names are interchangeable and represent branding name vs. internal descriptive name.
More Information

No
The 510(k) summary describes a guidewire with pacing capabilities and focuses on standard performance testing (sterilization, biocompatibility, mechanical testing). There is no mention of AI, ML, image processing, or data sets for training/testing algorithms.

Yes

The device aids in temporary intracardiac pacing, which is a therapeutic function for the heart.

No

The device is primarily used to introduce and position interventional devices and for temporary intracardiac pacing. These are interventional/therapeutic actions, not diagnostic ones.

No

The device description explicitly states it is a guidewire, which is a physical hardware component. The performance studies also detail testing related to sterilization, packaging, shelf-life, biocompatibility, and mechanical properties, all indicative of a physical device.

Based on the provided information, the PacePro Wire is not an In Vitro Diagnostic (IVD) device.

Here's why:

  • Intended Use: The intended use clearly describes the device's function as introducing and positioning interventional devices within the heart and for temporary intracardiac pacing. These are direct interactions with the patient's body, not tests performed on samples taken from the body.
  • Device Description: The description confirms it's a guidewire with structural and pacing functions, again indicating direct patient interaction.
  • Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, tissue, etc.), detecting analytes, or providing diagnostic information based on laboratory testing.

IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The PacePro Wire's function is procedural and therapeutic (pacing), not diagnostic in the IVD sense.

N/A

Intended Use / Indications for Use

The PacePro Wire is intended for use to introduce and position interventional devices within the chambers of the heart, including those used for transcatheter aortic valve procedures.

Additionally, the PacePro Wire can be used for temporary intracardiac pacing by transmitting an electrical signal from an external pulse generator to the heart.

Product codes (comma separated list FDA assigned to the subject device)

DQX, LDF

Device Description

The proposed PacePro Wire is a guidewire that includes functions for a structural wire and a pacing wire (temporary intracardiac pacing by transmitting an electrical signal from an external pulse generator to the heart.). Throughout the submission this will be referred to as either PacePro Wire or Opsens Pacing Wire (OPW). These two names are interchangeable and represent branding name vs. internal descriptive name.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Chambers of the heart

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Sterilization, Packaging, Shelf-life Testing:
The following standards are utilized to show equivalence of Sterilization, Packaging, and Shelf life:

  • ISO 11135-1 (2014) Sterilization of health-care products - ethylene oxide - requirements for the development, validation and routine control of a sterilization process for medical devices. (Sterility)
  • ISO 11607-1 (2019) – Amendment 1:2023 Packaging for terminally sterilized medical devices - part 1: requirements for materials, sterile barrier systems and packaging systems

Biocompatibility testing:
The biocompatibility evaluation was conducted in accordance with the FDA guidance Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process" (Attachment A) published June 16, 2016. This device is categorized in ISO 10993-1:2018 as "External communicating device – circulating blood" per section 5.2.3 c). The device will have limited exposure, a cumulative sum of single, multiple or repeated duration of contact up to 24 h. Testing completed on this device includes:

  • Cytotoxicity
  • Sensitization
  • Intracutaneous reactivity
  • Systemic toxicity (acute)
  • Hemocompatibility
  • Pyrogenicity
  • SC5b-9 complement

Design Verification:
Testing was conducted based on requirements of the latest FDA guidance document on guidewires: FDA Guidance Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling Guidance for Industry and Food and Drug Administration Staff October 2019. All Design Requirements were successfully verified for the PacePro Wire device.

Design verification testing included:

  • Mechanical Testing
  • Particulate Testing
  • Rapid Pacing Testing

No new questions of safety and effectiveness were identified during execution of Verification and Validation activities.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K213854

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

K151244, K191907

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 870.1330 Catheter guide wire.

(a)
Identification. A catheter guide wire is a coiled wire that is designed to fit inside a percutaneous catheter for the purpose of directing the catheter through a blood vessel.(b)
Classification. Class II (special controls). The device, when it is a torque device that is manually operated, non-patient contacting, and intended to manipulate non-cerebral vascular guide wires, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.

0

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: a symbol on the left and the FDA name and title on the right. The symbol on the left is a stylized representation of a human figure, while the text on the right reads "FDA U.S. FOOD & DRUG ADMINISTRATION" in blue letters.

May 24, 2024

Opsens Inc. Marc Chaunet Regulatory Affairs Director 750. Boulevard du Parc Technologique Quebec, QC G1P 4S3 Canada

Re: K240864

Trade/Device Name: PacePro Wire Regulation Number: 21 CFR 870.1330 Regulation Name: Catheter Guide Wire Regulatory Class: Class II Product Code: DQX, LDF Dated: March 27, 2024 Received: March 28, 2024

Dear Marc Chaunet:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

1

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Image /page/1/Picture/8 description: The image shows a digital signature. The signature is for Sara M. Royce. The date of the signature is 2024.05.24, and the time is 12:10:01 -04'00'.

Sara Royce Assistant Director DHT2A: Division of Cardiac Electrophysiology, Diagnostics

2

and Monitoring Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

3

Indications for Use

510(k) Number (if known) K240864

Device Name PacePro Wire

Indications for Use (Describe)

The PacePro Wire is intended for use to introduce and position interventional devices within the chambers of the heart, including those used for transcatheter aortic valve procedures.

Additionally, the PacePro Wire can be used for temporary intracardiac pacing by transmitting an electrical signal from an external pulse generator to the heart.

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)☑ Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)
☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

4

Image /page/4/Picture/0 description: The image shows the logo for "opSens". The "op" is in orange, and the "Sens" is in gray. There are three orange dots above the "e" in "Sens".

510(K) Summary for PacePro Wire

SUBMITTER 1.

Address: Opsens Inc.

750, Boulevard du Parc Technologique

Quebec (Quebec) G1P 4S3

Phone: 418.781.0333 ext 3408

Fax Number: 418-781-0024

Contact Person: Marc Chaunet, Regulatory Affairs Director

Email: marc.chaunet@opsens.com

Date Prepared: March 27, 2024

DEVICE 2.

Name of Device: PacePro Wire

Common or Usual Name: Structural guidewire with temporary pacing capabilities

Classification name: Wire, guide, catheter; electrode, pacemaker, temporary

Regulatory Class: II Product

Code: DQX, LDF

PREDICATE DEVICE 3.

The proposed PacePro Wire™ is substantially equivalent to the Opsens existing guidewire, SavyWire™ cleared in K213854 on 09/14/2022.

The subject device is physically the same product as the SavvyWire, without the pressure sensing capabilities. The predicate device has not been subject to a design-related recall.

4. DEVICE DESCRIPTION

The proposed PacePro Wire is a guidewire that includes functions for a structural wire and a pacing wire (temporary intracardiac pacing by transmitting an electrical signal from an external pulse generator to the heart.). Throughout the submission this will be referred to as either PacePro Wire or Opsens Pacing Wire (OPW). These two names are interchangeable and represent branding name vs. internal descriptive name.

5

5. INDICATIONS FOR USE

The PacePro Wire is intended for use to introduce and position interventional devices within the chambers of the heart, including those used for transcatheter aortic valve procedures.

Additionally, the PacePro Wire can be used for temporary intracardiac pacing by transmitting an electrical signal from an external pulse generator to the heart.

COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE 6. DEVICE

The proposed PacePro Wire is substantially equivalent to the SavvyWire™ cleared in K213854 on 09/14/2022.

The proposed PacePro Wire indications for use are essentially the same as for the SawyWire, minus the following portion "while measuring the pressure within the heart allowing calculation of hemodynamic parameters" as the subject device does not feature the pressurement capabilities of the cleared predicate SavvyWire.

The technological characteristics of the proposed PacePro Wire encompass the functionalities of the predicate device including functions for a structural wire, and a pacing wire (temporary intracardiac pacing by transmitting an electrical signal from an external pulse generator to the heart). Each of these functions is fully supported by the relevant predicate device. Identical to the SawyWire, the PacePro Wire is unipolar. This necessitates the use of a separate patient electrode for the positive connection to the external pulse generator. The pacing capabilities of the PacePro Wire is tested to be equivalent to that of the predicate device. No new questions of safety and effectiveness were identified during the execution of Verification and Validation activities.

Therefore, the proposed devices, PacePro Wire meets substantial equivalence requirements with regards to the legally marketed predicate SavvyWire cleared in K213854.

For detailed comparison, refer to the Substantial Equivalence table on the following pages.

Proposed DevicePredicate DeviceDifferences
Regulatory InformationNamePace Pro WireSavvyWire™N/A
510(k)#PendingK213854N/A
PredicatesK213854K151244, K191907N/A
Product CodeDQX, LDFDQX, DXO, LDFSame except for DXO
Class22Same
Regulation
Number870.1330, 870.3680870.1330, 870.2870, 870.3680Same except for 870.2870
Regulation
Generic NameWire, guide, catheter; electrode, pacemaker, temporaryWire, guide, catheter; Transducer, pressure, catheter tip, electrode, pacemaker, temporarySame except for "Transducer,

T ABLE 1: PACEPRO WIRE COMPARISON TABLE

6

Image /page/6/Picture/0 description: The image shows the logo for OpSens. The "op" part of the name is in orange, while the "Sens" part is in gray. There are three orange dots above the "Sens" part of the name. The logo is simple and modern.

| | | pressure, catheter
i tip" |
|--|--|------------------------------|
| | | |

Proposed DevicePredicate DeviceDifferences
Intended useRegulation
Intended UseCoiled wire fits inside a
percutaneous catheter for the
purpose of directing the
catheter through a blood
vessel.
The device is used to transmit
a pacing electrical stimulus
from the pulse generator to
the heart and/or to transmit
the electrical signal of the
heart to the pulse generator.Coiled wire fits inside a percutaneous
catheter for the purpose of directing the
catheter through a blood vessel.
Catheter tip transmits mechanical or
electrical property changes in relation to
changes in blood pressure to accessory
equipment for processing.
The device is used to transmit a pacing
electrical stimulus from the pulse
generator to the heart and/or to transmit
the electrical signal of the heart to the
pulse generator.Same except for
"Catheter tip
transmits
mechanical or
electrical property
changes in relation
to changes in blood
pressure to
accessory
equipment for
processing."
IndicationsThe PacePro Wire™ is
intended for use to introduce
and position interventional
devices within the chambers
of the heart, including those
used for transcatheter aortic
valve procedures.
Additionally, the PacePro
Wire™ can be used for
temporary intracardiac
pacing by transmitting an
electrical signal from an
external pulse generator to
the heart.The SavvyWire™ is intended for use to
introduce and position interventional
devices within the chambers of the
heart, including those used for
transcatheter aortic valve procedures,
while measuring the pressure within the
heart allowing calculation of
hemodynamic parameters.
Additionally, the SavvyWire™ can be
used for temporary intracardiac pacing
by transmitting an electrical signal from
an external pulse generator to the heart.Same except for
"while measuring
the pressure within
the heart allowing
calculation of
hemodynamic
parameters" not
relevant for the
subject device
PacePro Wire.
ContraindicationsCerebral vasculature &
absence of anti-coagulation
therapyCerebral vasculature & absence of
anticoagulation therapySame
Prescription UseRx OnlyRx OnlySame
System
ComponentsSterile, disposable guidewireSterile, disposable guidewireSame
Technological Characteristi
Pressure Sensing
& Signal
Transmission
TechnologyN/AFiberoptic sensor & fiber bundle
embedded in guidewire.There are no
fiberoptic sensor &
fiber bundle
embedded in the
PacePro Wire
guidewire
Sterile, Single
Use Patient
Contact
Component?YesYesSame

7

Image /page/7/Picture/0 description: The image shows the logo for "opSens". The "op" is in orange, while the "Sens" is in gray. There are three orange dots above the "ens" in the logo.

Guidewire OD0.035"0.035"Same
Guidewire
Length280 cm280 cmSame
Guidewire Shaft
MaterialStainless steelStainless steelSame
Tip CoatingNone (Stainless steel)None (Stainless steel)Same
Shaft CoatingTeflon (PTFE)Teflon (PTFE)Same
Intermediate
Section CoatingTeflon (PTFE)Teflon (PTFE)
Tip ConfigurationSpiral (XS OD 3.2 cm,
S OD 4.2 cm)Spiral (XS OD 3.2 cm,
S OD 4.2 cm)Same
Proposed DevicePredicate DeviceDifferences
Guidewire Tip
DesignCoiledCoiledSame
Guidewire Tip
LengthXS: 2.9 cm
S: 3.8 cmXS: 2.9 cm
S: 3.8 cmSame
Radiopaque Tip?YesYesSame
Pressure Sensor
LocationXS: 2.9 cm
S: 3.8 cmXS: 2.9 cm
S: 3.8 cmSame
ElectrodeUnipolarUnipolarSame
External Pulse
Generator
ConnectionAlligator clamp (negative
lead) is connected to one of
the PacePro Wire pacing
connection zonesAlligator clamp (negative lead) is
connected to one of the SavvyWire
pacing connection zonesSame
Pulse Generator
compatibilityCompatible with standard
external pulse generatorsCompatible with standard external pulse
generatorsSame

PERFORMANCE DATA 7.

Sterilization, Packaging, Shelf-life Testing:

The following standards are utilized to show equivalence of Sterilization, Packaging, and Shelf life:

  • ISO 11135-1 (2014) Sterilization of health-care products - ethylene oxide - requirements for the development, validation and routine control of a sterilization process for medical devices. (Sterility)
  • . ISO 11607-1 (2019) – Amendment 1:2023 Packaging for terminally sterilized medical devices - part 1: requirements for materials, sterile barrier systems and packaging systems

Biocompatibility testing:

The biocompatibility evaluation was conducted in accordance with the FDA guidance Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process" (Attachment A) published June 16, 2016. This device is categorized in ISO

8

10993-1:2018 as "External communicating device – circulating blood" per section 5.2.3 c). The device will have limited exposure, a cumulative sum of single, multiple or repeated duration of contact up to 24 h. Testing completed on this device includes:

  • Cytotoxicity
  • . Sensitization
  • Intracutaneous reactivity
  • . Systemic toxicity (acute)
  • . Hemocompatibility
  • . Pyrogenicity
  • SC5b-9 complement

Design Verification:

Testing was conducted based on requirements of the latest FDA guidance document on guidewires: FDA Guidance Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling Guidance for Industry and Food and Drug Administration Staff October 2019. All Design Requirements were successfully verified for the PacePro Wire device.

Design verification testing included:

  • Mechanical Testing
  • Particulate Testing
  • . Rapid Pacing Testing

No new questions of safety and effectiveness were identified during execution of Verification and Validation activities.

Animal studies:

No animal studies were necessary in support of the substantial equivalence of the PacePro Wire as the intended use/indications for use and technological characteristics are equivalent to the predicate device.

Clinical Studies

No clinical studies were necessary in support of the substantial equivalence of the PacePro Wire as the intended use/indications for use and technological characteristics are equivalent to the predicate device.

8. CONCLUSIONS

The results from these tests mentioned above demonstrate that the technological and performance characteristics of the PacePro Wire is comparable to the predicate device, supports the substantial equivalence of the device that is the subject of this 510(k), and ensures the subject device can perform in a manner equivalent to the predicate device for the shared intended use.

9

Image /page/9/Picture/0 description: The image shows the logo for "opSens". The "op" is in orange, and the "Sens" is in gray. There are three orange dots above the "s" in "Sens".

The results of the verification/validation tests have demonstrated that the PacePro Wire does not raise any new questions of safety and efficacy and is therefore substantially equivalent to the legally marketed predicate device, the SavvyWire cleared in K213854.